Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study

Atezolizumab plus bevacizumab treatment is a first-line therapy for unresectable hepatocellular carcinoma (HCC) worldwide. The efficacy, safety, and patient-reported outcomes (PROs) of HCC in Thailand have not yet been reported. This study aimed to evaluate the efficacy, safety, and PROs of atezoliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Charonpongsuntorn, Chanchai, Tanasanvimon, Suebpong, Korphaisarn, Krittiya, Payapwattanawong, Songwit, Siripoon, Teerada, Pakvisal, Nussara, Juengsamarn, Jitlada, Phaibulvatanapong, Ekkamol, Chindaprasirt, Jarin, Prasongsook, Naiyarat, Udomdamrongkul, Kittipong, Ngamphaiboon, Nuttapong, Sirachainan, Ekaphop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166432/
https://www.ncbi.nlm.nih.gov/pubmed/36455172
http://dx.doi.org/10.1200/GO.22.00205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166432/
https://www.ncbi.nlm.nih.gov/pubmed/36455172
http://dx.doi.org/10.1200/GO.22.00205

Ejemplares similares